nuclei with central nucleoli and eosinophilic pink vacuolated cytoplasm. These cells are arranged into microcystic, cribriform, tubular, papillary, follicular (thyroid like), or solid nests ( Figure 1 ). Microscopic foci of invasion are often present, but the overall mitotic activity is low. Intraluminal secretions may be seen in the microcystic or tubular structures. Such material is usually mucicarmine, periodic acid-Schiff (PAS), and alcian blue positive. It also stains with antibodies to epithelial membrane antigen (EMA). The unique microscopic features of MASC can be also recognized cytologically by fine-needle aspiration biopsy [3, 4] .
Immunohistochemistry: As expected for carcinomas, tumor cells are positive for wide-spectrum cytokeratins (e.g. AE1/AE3, Cam5.2) and low-molecular weight cytokeratins (CK7, CK8, CK19). They are also positive for vimentin, S-100, mammaglobin, GCDFP-15, MUC1, GATA-binding protein 3, adipophilin, α-amylase, DOG-1, SOX-10, and p63 [1, 2] . Using these IHC markers Urano et al. found some variations among the tumors and identified 3 histologic subtypes [5] .
Genetics: Fluorescent in situ hybridization (FISH) analysis will demonstrate in most instances a t(12;15)(p13;q25) translocation with ETV6-NTRK3 gene fusion, which can be proven by means of molecular biology (e.g. RT-PCR). Cases without classical ETV6 gene rearrangement may harbor alternative gene rearrangements ("ETV6-X fusion") that may be associated with more aggressive clinical course of the disease [6, 7] .
Differential diagnosis: Includes acinic cell carcinoma, mucoepidermoid carcinoma, and low-grade cribriform cystadenocarcinoma of the salivary gland.
Clinical course and outcome: MASC is most often found in the parotid glands, but it may occur in other glands including the minor salivary glands. In most instances the diagnosis of MASC carries a good prognosis and the neoplastic disease has an indolent clinical course [1, 5, 7] . Not all MASC have a good prognosis and a high-grade transformation followed by an accelerated clinical course and poor outcome has also been recorded in three patients [8] . Genetic analysis of tumors may identify tumors of a more aggressive nature [7] .
Currently, no specific therapy is available for patients with MASC. Of note, Drilon et al. described a case with the patient with molecularly confirmed MASC that had a dramatic and clinically durable response to the targeted therapy with the pan-Trk inhibitor entrectinib (Ignyta) [9] . This drug has been shown to exhibit a potent in vitro activity against cell lines that contain various NTRK1/2/3 fusions. The patient developed resistance to the drug later in the course of the disease due to the NTRK3 G623R mutation.
Epidemiology: The true incidence of MASC is currently unknown due to its rarity and previous misclassification of this tumor type. Luk et al. found 9 MASC in a review of 190 malignant salivary gland tumors (~4.5%), whereas Majewska et al. found 7 MASC out of 183 cases (~4%) in a similar study [10, 11] . MASC has a more or less equal distribution between men and women, in most studies showing slight (1.3 to 1.5) male predominance.
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